NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: BASF

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BASF Pharma Solutions and IFF Pharma Solutions Establish Collaboration on Virtual Pharma Assistant Platform ZoomLab™ - IFF’s and BASF’s Pharma Solutions divisions have joined forces in a collaboration to onboard IFF’s leading product brands in pharmaceutical excipients on BASF’s Virtual Pharma Assistant platform ZoomLab™ [NYSE: IFF] - IFF.com / Pharma.BASF.com
BASF Pharma Solutions and IFF Pharma Solutions Establish Collaboration on Virtual Pharma Assistant Platform ZoomLab™

 

NewswireTODAY - /newswire/ - Florham Park, NJ, United States, 2023/11/08 - IFF’s and BASF’s Pharma Solutions divisions have joined forces in a collaboration to onboard IFF’s leading product brands in pharmaceutical excipients on BASF’s Virtual Pharma Assistant platform ZoomLab™ [NYSE: IFF] - IFF.com / Pharma.BASF.com. Frankfurt (BAS)

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• The collaboration brings a seamless digital experience to more formulators worldwide;
• The first phase will make IFF’s leading product brands Avicel® and Ac-Di-Sol® available to users in ZoomLab™;
• Users can find IFF ingredients in ZoomLab™ Excipient Database and throughout the different ZoomLab™ modules.

The platform is a science-based digital tool designed to rapidly and accurately predict the best excipients needed for the development of new pharmaceutical formulations to help overcome formulation challenges.

The collaboration between IFF and BASF aligns with the companies’ shared values on customer-centricity and the goal to bring a seamless digital experience to more formulators worldwide. Powered by BASF’s proprietary algorithm, ZoomLab™ allows formulators to accelerate formulation design by predicting the most effective excipients to match a given active pharmaceutical ingredient. It also allows them to make customizations, offering a range of ingredients to choose from including IFF’s renowned high-quality excipients.

In the first phase of the collaboration, IFF’s product line Avicel® microcrystalline cellulose (MCC) and super disintegrant Ac-Di-Sol® croscarmellose sodium will be available to users in ZoomLab™ Excipient Database and throughout the various ZoomLab™ modules. Formulators and ZoomLab™ users will benefit through this broadened access to excipients to solve their formulation challenges.

“Our collaboration with IFF aligns well with our commitment to provide exceptional value to our customers through our digital Virtual Pharma Assistants. Including IFF products within ZoomLab™ underlines our ambition to continuously develop ZoomLab™ into the leading industry platform giving users access to a broad range of excipients and make it even easier to create formulations quickly,” said Jeffrey DeAlmeida, senior vice president, BASF Pharma Solutions and Nutrition and Health, Americas. “We will continue to deepen our collaboration on ZoomLab™ in the future including more content and features for users.”

“At IFF, we apply a customer-centric approach to problem-solving throughout the drug development process. We are committed to being the partner our customers can count on, and now thanks to our exciting collaboration with BASF on ZoomLab™ we are helping even more customers innovate and overcome their formulation challenges,” said Angela Strzelecki, president, IFF Pharma Solutions. “The addition of our renowned ingredients into this platform enhances the ability of ZoomLab™ to predict the best formulations and accelerates the launch of more innovative products across the global pharmaceutical market which is good for manufacturers and patients around the world.”

About ZoomLab™

ZoomLab™ (pharma.basf.com) is a science-based digital tool that allows formulators to predict their next drug’s starting formulations and solve other formulation challenges. ZoomLab™ is available online.

About BASF

At BASF (basf.com), we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. More than 111,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of €87.3 billion in 2022.

About IFF

At IFF (iff.com), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: BASF

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BASF Pharma Solutions and IFF Pharma Solutions Establish Collaboration on Virtual Pharma Assistant Platform ZoomLab™

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
ZoomLab™ | BASF Pharma
Contact: John Bell - BASF.com 
848 200-8874 john.bell[.]basf.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any BASF securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From BASF / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Onivyde® Regimen, A Potential New Standard-of-care First-line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
Frost & Sullivan and Trautec have Conducted An Extensive Investigation Across the Recombinant Type XVII Collagen Industry Chain
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Bushu Pharma Recognized with Frost & Sullivan’s 2023 Japan Customer Value Leadership Award for Offering Advanced Pharmaceutical Manufacturing
STEMCELL Technologies Wins a Canada’s Most Admired Corporate Cultures™ of 2023 Award
BASF Invests in Start-up 3Helix, Inc. to Jointly Bring Collagen-hybridizing Peptide Solutions to the Personal Care Market
BASF Aroma Ingredients Expands its Isobionics® Portfolio with New Natural Flavors
Thales and Bertin Partner in CBRN Defence with Successful Tests of Biological Sampling and Identification for the PIABC PELICAN
Ipsen Updates on E.U. Marketing Authorisation Application for Odevixibat in Alagille Syndrome
BASF Pharma Solutions Introduces 'VPA Premium Services' to its Virtual Pharma Assistants (VPAs) Digital Services Platform
NEC Selected by AMED for Design of A Universal Vaccine that is Effective Against Influenza Virus Strains
BostonGene, NEC and JIP Form Joint Venture in Japan
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib
US FDA Approves Ipsen’s Sohonos™ (palovarotene) Capsules, the First and Only Treatment for People with Fibrodysplasia Ossificans Progressiva
SCHOTT Pharma Strengthens Leading Position in the First Year as Stand-alone Company

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  BizJobs.com





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)